Developing therapies for muscular dystrophy and spinal muscular atrophy

Advancement in Gene Therapy Across Neuromuscular DiseasesПодробнее

Satellos (MSCL) CEO Frank Gleeson & CFO Liz Williams - Product Development and MilestonesПодробнее

Strength in Genes: Gene Therapy's Potential for Treating Muscular Dystrophy #musculardystrophyПодробнее

Ultrarare patient journey and drug development for ZTTKПодробнее

Overview of the CMT Drug Development PipelineПодробнее

2023 International LGMD Conference Session #3Подробнее

Family Forum 2023: Session 1 - Research & Drug Development UpdatesПодробнее

Fetal Therapy Development | Spinal Muscular Atrophy 2023Подробнее

Improving Diagnostics & Gene Discovery & Dev Treatments Research Evening 2024Подробнее

Pediatric Rehabilitation - Cerebral Palsy, Muscular Dystrophy, BDA Therapy & Pragma SystemПодробнее

Atypical Development Baby Early Signs of Rare Genetics, Q Muscular Dystrophy or SMAПодробнее

Goodfellow Unit Webinar: Spinal Muscular AtrophyПодробнее

Keynote SessionПодробнее

The mechanism and development of nusinersen for SMAПодробнее

The Development of Cognition and Communication Skills in SMA Type 1 - Oct 2023Подробнее

The Development of New Gene Therapies to Address Unmet Needs in ALSПодробнее

Indian Japan Doctors Develops Treatment on Muscular DystrophyПодробнее

Satellos Bioscience aims to advance the clinical development of medicine related to muscle disordersПодробнее

MDA Advocacy Institute: Policies Influencing Gene Therapy Development 1Подробнее

Comparing Gene Therapies Across ProgramsПодробнее